156
Views
1
CrossRef citations to date
0
Altmetric
Menopause

Effect of sulpiride on menopausal hot flashes: a randomized, double-blind, placebo-controlled clinical trial

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon
Pages 247-251 | Received 12 May 2019, Accepted 18 Aug 2019, Published online: 03 Sep 2019

References

  • Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015;175:531–539.
  • Sturdee DW, Hunter MS, Maki PM, et al. The menopausal hot flush: a review. Climacteric. 2017;20:296–305.
  • Sriprasert I, Pantasri T, Piyamongkol W, et al. An international menopause society study of vasomotor symptoms in Bangkok and Chiang Mai, Thailand. Climacteric. 2017;20:171–177.
  • Santoro N, Epperson CN, Mathews SB. Menopausal symptoms and their management. Endocrinol Metab Clin North Am. 2015;44:497–515.
  • Hill DA, Crider M, Hill SR. Hormone therapy and other treatments for symptoms of menopause. Am Fam Physician. 2016;94:884–889.
  • Rindner L, Strömme G, Nordeman L, et al. Reducing menopausal symptoms for women during the menopause transition using group education in a primary health care setting-a randomized controlled trial. Maturitas. 2017;98:14–19.
  • Daley A, Stokes-Lampard H, Thomas A, et al. Exercise for vasomotor menopausal symptoms. Cochrane Database Syst Rev. 2014;11:CD006108.
  • Marjoribanks J, Farquhar C, Roberts H, et al. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2017;1:CD004143.
  • Langer RD. The evidence base for HRT: what can we believe? Climacteric. 2017;20:91–96.
  • Goldstein KM, McDuffie JR, Shepherd-Banigan M, et al. Nonpharmacologic, nonherbal management of menopause-associated vasomotor symptoms: an umbrella systematic review (protocol). Syst Rev. 2016;5:56.
  • Lethaby A, Marjoribanks J, Kronenberg F, et al. Phytoestrogens for menopausal vasomotor symptoms. Cochrane Database of Syst Rev. 2013;12:CD001395.
  • Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA. 2006;295:2057–2071.
  • Pinkerton JV, Joffe H, Kazempour K, et al. Low-dose paroxetine (7.5 mg) improves sleep in women with vasomotor symptoms associated with menopause. Menopause. 2015;22:50–58.
  • Stearns V, Beebe KL, Iyengar M, et al. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA. 2003;289:2827–2834.
  • Abbas AI, Hedlund PB, Huang XP, et al. Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology (Berl). 2009;205:119–128.
  • World Medical Association. World medical association declaration of Helsinki ethical principles for medical research involving human subjects. JAMA. 2013;310:2191–2194.
  • Abramson JH. WINPEPI (PEPI-for-Windows): computer programs for epidemiologists. Epidemiol Perspect Innov. 2004;1:6.
  • Simon JA, Chandler J, Gottesdiener K, et al. Diary of hot flashes reported upon occurrence: results of a randomized double-blind study of raloxifene, placebo, and paroxetine. Menopause. 2014;21:938–944.
  • Carpenter JS, Guthrie KA, Larson JC, et al. Effect of escitalopram on hot flash interference: a randomized, controlled trial. Fertil Steril. 2012;97:1399–1404.e1.
  • Deeks JJ, Higgins JPT, on behalf of the Statistical methods group of the Cochrane collaboration. Statistical algorithms in review manager5. 2010;5: 3–10.
  • Schulz KF, Altman DG, Moher D, et al. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Obstet Gynecol. 2010;115:1063–1070.
  • Linquette M, Rivière J, Vague J. [Non-hormonal therapy for menopausal disorders: results of a multicentric double-blind trial (author’s transl)]. Sem Hop. 1980;56:1445–1448.
  • Carretti N, Florio P, Reis FM, et al. Reduction of serum serotonin precursors after veralipride treatment for postmenopausal hot flushes. Climacteric. 2010;13:141–146.
  • Carranza-Lira S. Actual status of veralipride use. Clin Interv Aging. 2010;5:271–276.
  • Valencia MH, Arias MJ, González CC, et al. Safety of veralipride for the treatment of vasomotor symptoms of menopause. Menopause. 2014;21:484–492.
  • Pachman DR, Jones JM, Loprinzi CL. Management of menopause-associated vasomotor symptoms: current treatment options, challenges and future directions. Int J Womens Health. 2010;2:123–135.
  • Oakley AE, Steiner RA, Chavkin C, et al. κ Agonists as a novel therapy for menopausal hot flashes. Menopause. 2015;22:1328–1334.
  • Cesarani A, Alpini D, Monti B, ENT Department, University of Milan, Milan, Italy, et al. The treatment of acute vertigo. Neurol Sci. 2004;25:S26–S30.
  • Pérez-López FR, Abós MD. Pituitary hormonal response to the orthopramides clebopride, bromopride, metoclopramide, and sulpiride. Fertil Steril. 1982;37:445–448.
  • Rance NE, Dacks PA, Mittelman-Smith MA, et al. Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: a novel hypothesis on the mechanism of hot flushes. Front Neuroendocrinol. 2013;34:211–227.
  • Skorupskaite K, George JT, Anderson RA. The kisspeptin-GnRH pathway in human reproductive health and disease. Hum Reprod Update. 2014;20:485–500.
  • Li L, Xu L, Wu J, et al. Quantitative analysis of placebo response and factors associated with menopausal hot flashes. Menopause. 2017;24:932–937.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.